356 related articles for article (PubMed ID: 19689275)
1. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.
Matteucci E; Giampietro O
Curr Med Chem; 2009; 16(23):2943-51. PubMed ID: 19689275
[TBL] [Abstract][Full Text] [Related]
2. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.
Wagner L; Klemann C; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jun; 184(3):265-83. PubMed ID: 26671446
[TBL] [Abstract][Full Text] [Related]
3. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
Klemann C; Wagner L; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
[TBL] [Abstract][Full Text] [Related]
4. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview.
Bernstein HG; Keilhoff G; Dobrowolny H; Steiner J
Rev Neurosci; 2023 Jan; 34(1):1-24. PubMed ID: 35771831
[TBL] [Abstract][Full Text] [Related]
5. N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding.
Aertgeerts K; Ye S; Shi L; Prasad SG; Witmer D; Chi E; Sang BC; Wijnands RA; Webb DR; Swanson RV
Protein Sci; 2004 Jan; 13(1):145-54. PubMed ID: 14691230
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment.
Janardhan S; Sastry GN
Curr Drug Targets; 2014 Jun; 15(6):600-21. PubMed ID: 24611684
[TBL] [Abstract][Full Text] [Related]
7. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
Zhong J; Rao X; Rajagopalan S
Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
[TBL] [Abstract][Full Text] [Related]
8. Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.
Zettl H; Schubert-Zsilavecz M; Steinhilber D
ChemMedChem; 2010 Feb; 5(2):179-85. PubMed ID: 20029928
[No Abstract] [Full Text] [Related]
9. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
[TBL] [Abstract][Full Text] [Related]
11. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
Jackson EK; Mi Z; Tofovic SP; Gillespie DG
Hypertension; 2015 Jan; 65(1):238-49. PubMed ID: 25368027
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Mulvihill EE
Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
14. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Winkler G
Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
[TBL] [Abstract][Full Text] [Related]
15. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
[TBL] [Abstract][Full Text] [Related]
16. Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4.
Lettau M; Dietz M; Vollmers S; Armbrust F; Peters C; Dang TM; Chitadze G; Kabelitz D; Janssen O
Cell Mol Life Sci; 2020 Feb; 77(4):751-764. PubMed ID: 31300870
[TBL] [Abstract][Full Text] [Related]
17. More effective DPP4 inhibitors as antidiabetics based on sitagliptin applied QSAR and clinical methods.
Buiu C; Avram S; Duda-Seiman D; Milac AL; Duda-Seiman C; Pacureanu L; Borcan F
Curr Comput Aided Drug Des; 2014; 10(3):237-49. PubMed ID: 25756669
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin.
Lyseng-Williamson KA
Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.
Durinx C; Lambeir AM; Bosmans E; Falmagne JB; Berghmans R; Haemers A; Scharpé S; De Meester I
Eur J Biochem; 2000 Sep; 267(17):5608-13. PubMed ID: 10951221
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]